SGLT2 Inhibitor’s Heart Benefit Extended
A systematic review and meta-analysis concluded that sodium–glucose cotransporter-2 (SGLT2) inhibitors reduced hospitalizations for heart failure (HF) regardless of the presence of diabetes. The analysis included trials that randomly assigned adults with HF to SGLT2 inhibitors or control. Time-to-event individual patient data were reconstructed from published Kaplan–Meier plots; time-varying risk […]